RecruitingNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.
Sponsor: Washington University School of Medicine
You may qualify if…
- ✓ Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC.
- ✓ Availability of archival biopsy tissue or willingness to undergo a biopsy prior to C1D1 for biomarker analysis, including PD-L1 by IHC using a CLIA-certified test. Results of the PD-L1 testing are not required for enrollment.
- ✓ Measurable disease per RECIST 1.1.
- ✓ At least 18 years of age.
- ✓ ECOG performance status ≤ 1
- ✓ Adequate organ and marrow function, as defined below:
- ✓ Absolute neutrophil count ≥ 1.5 K/cumm
- ✓ Platelets ≥ 100 K/cumm
You may not qualify if…
- ✕ Mixed histology including small cell lung cancer.
- ✕ Tumor harboring any of the following:
- ✕ classic EGFR mutations
- ✕ HER2 mutation
- ✕ ALK fusion
- ✕ ROS1 fusion
- ✕ RET fusion
- ✕ NTRK fusion
Where it's recruiting
Missouri
St Louis
Source: ClinicalTrials.gov · NCT07355205 · last updated 2026-07-10